© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
November 25, 2014
A drug to treat acquired hemophilia A was approved by the FDA, according to a statement made by manufacturer Baxter International Inc.
The FDA has approved Rixubis for the treatment of hemophilia B in children, manufacturer Baxter International Inc. announced.
Nonacog beta pegol was well-tolerated and effective for treatment of bleeding episodes in hemophilia B patients, and was associated with low annualized bleeding rates.
Inhibitor screening is important for all hemophilia patients, not just those at high risk, according to a study by the CDC.
Companies will use cell line development studies to determine where factor VIII manufacturing costs can be lowered without sacrificing efficacy.
During surgery, rFIXFc controlled hemophilia patients' perioperative bleeding, according to a study published in the British Journal of Haemotology.